Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 439
- Registration Number
- NCT00620061
- Locations
- 🇺🇸
Clinical Research Advantage, Inc., Tempe, Arizona, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Orange County Clinical Trials, Anaheim, California, United States
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
- Conditions
- UlcersOsteoarthritisNSAID-induced Gastroduodenal InjuryRheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 121
- Registration Number
- NCT00597818
- Locations
- 🇺🇸
Gastroenterology Section at Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Dallas VA Research Corporation, Inc., Dallas, Texas, United States
🇺🇸Gulf Coast Research, LLC, Baton Rouge, Louisiana, United States
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
- Conditions
- Opioid-Induced Bowel Dysfunction
- Interventions
- Drug: PlaceboDrug: Lubiprostone
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 437
- Registration Number
- NCT00597428
- Locations
- 🇺🇸
Claude Mandel Medical Center, Chicago, Illinois, United States
🇺🇸Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States
🇺🇸Hampton Roads Institute for Performance and Sports Medicine (HIPS), Portsmouth, Virginia, United States
Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
- Conditions
- Opioid-Induced Bowel Dysfunction
- Interventions
- Drug: PlaceboDrug: Lubiprostone
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 439
- Registration Number
- NCT00595946
- Locations
- 🇺🇸
Orange County Clinical Trials, Inc., Anaheim, California, United States
🇺🇸Apex Medical Research, AMR, Inc., Flint, Michigan, United States
🇺🇸Medoff Medical/ Vital re:Search, Greensboro, North Carolina, United States
Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT00452335
- Locations
- 🇺🇸
University of Illinois at Chicago, Springfield, Illinois, United States
🇺🇸Arkansas Pediatric Clinic, Little Rock, Arkansas, United States
🇺🇸AHS Hospital Corporation, Morristown, New Jersey, United States
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
- Conditions
- ConstipationIrritable Bowel Syndrome
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 581
- Registration Number
- NCT00399542
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
- Conditions
- Irritable Bowel Syndrome With Constipation
- Interventions
- Drug: PlaceboDrug: Lubiprostone
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Target Recruit Count
- 590
- Registration Number
- NCT00380250